Galderma

FY 2025 results: Galderma achieved record net sales of 5.207 billion USD, surpassing annual sales of 5 billion USD for the first time, growing 17.7% year-on-year at constant currency. Read more: galderma.com/news/galderma-… #AdvancingDermatology #FYResults2025 $GALD

Galderma introduces ALASTIN’s Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based regenerative skincare. galderma.com/news/galderma-…

New interim data from two investigator‑initiated studies, proudly supported by Galderma, highlight the role of Sculptra® and Restylane® in addressing aesthetic changes associated with weight loss medications and menopause. Read more: bit.ly/3QbU9dD

Late-breaking phase II data will be presented at #AAD2026 in children with moderate-to-severe atopic dermatitis. Learn more: galderma.com/news/aad-2026-… #AdvancingDermatology #SkinScienceByGalderma

At the @AADskin meeting, 22 abstracts across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare, including late-breaking data in atopic dermatitis, will be presented. #AAD2026 galderma.com/news/aad-2026-…

Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support facial balance and harmony. Read more: galderma.com/news/galderma-… #SkinSciencebyGalderma

At #AMWC2026, Galderma will showcase data across Sculptra®, Restylane® and other injectable aesthetics products highlighting our holistic, future focused approach to aesthetics innovation. galderma.com/amwc-monaco-20… #AdvancingDermatology #SkinSciencebyGalderma

Galderma buys back shares worth CHF 232 million in the context of accelerated bookbuild offering. $GALD Read more: galderma.com/news/galderma-…

Galderma today announced the successful placement of a single-tranche EUR 500 million Eurobond. $GALD Read more: galderma.com/news/galderma-…

Galderma unveils #Cetaphil AM/PM Antioxidant Serums — a science-driven defense + recovery system designed for sensitive skin. Powered by Gallic-AOX Power™ Technology, delivering greater antioxidant efficacy than Vitamin C with visible results in 7 days. galderma.com/news/galderma-…

Our FY 2025 trading update call for investors takes place today, Thursday 5 March at 2 PM CET. Join live or watch the recording to learn about our record-breaking performance: investors.galderma.com/events-present…. #AdvancingDermatology #FYResults2025 $GALD

Beauty x Medicine returns with special guest Nicolas Hieronimus, CEO of L’Oréal. His four decades in the beauty industry have shown Nicolas that beauty isn’t just about meeting needs, but about “making dreams come true. Watch the full episode: youtube.com/watch?v=ksU_iR…

We are presenting new data on the long-term efficacy and safety of our treatment for prurigo nodularis for up to three years at 2026 Winter Clinical™ Miami. Learn more: galderma.com/news/galdermas… #AdvancingDermatology #SkinSciencebyGalderma #ForInvestors

@tazorack Hello! We have just sent a Direct Message on this platform with the specific email address you can use to reach our team.

@galderma can you guys respond to the inquiries? I sent feedback about your product weeks ago and still no response. Maybe your contact form does not work, and you need to give us an email address.

Galderma secures approval in the EU, U.S., and Canada for its next-generation Restylane® syringe. Developed with practitioners to enhance ergonomics and injection control, this state-of-the art syringe supports consistent results. Read more: galderma.com/news/galderma-…

We are pleased to announce the appointment of Luigi La Corte as CFO. He joins us with 30 years of financial leadership in healthcare and consumer businesses, and succeeds Thomas Dittrich. Read more: galderma.com/news/galderma-… #AdvancingDermatology

We’re uncovering stories from nine real and diverse patients. See how Sculptra® continues to prove its versatility as a regenerative treatment. Learn more: galderma.com/news/we-are-al… #AdvancingDermatology #Sculptra

Galderma expands the Restylane® portfolio in Japan with the launch of Restylane Defyne™ and Refyne™, the first OBT™-based HA injectables approved in the market, supporting continued momentum across the Japan & Asia Pacific region. bit.ly/3MA3ria

@tazorack Hello, thanks for your message, we have reached out via direct message.

@galderma can you please respond I have been trying to give you guys feedback on a product as it is not good but been a while now and still no response.

We’re excited to share that the U.S. #FDA has accepted the Biologics License Application resubmission for our anti-wrinkle treatment for frown lines and crow’s feet. Learn more: galderma.com/news/galderma-… #AdvancingDermatology